Updated: August 15, 2025 • Reading time: ~10 minutes
Medical disclaimer: This article is for educational purposes only and is not medical advice. Talk to a qualified clinician before using any supplement.
Why NAD+ still sits at the center of longevity talk
NAD+ powers energy metabolism and acts as a co-substrate for sirtuins, PARPs, and CD38. Levels fall with age. Raising NAD+ with precursors like NR and NMN can increase circulating NAD+ in humans; whether that consistently translates to hard clinical outcomes is still being studied.
The 2025 scoreboard: what’s credible—and what’s hype?
Nicotinamide riboside (NR)
Human data: Randomized trials show dose-dependent increases in NAD+ (≈100–1,000 mg/day over 6–12 weeks). Tolerability is generally good in short studies.
Pathways: NR → NAD+ → supports sirtuin/PARP activity (tissue-dependent effects).
Regulatory (U.S.): Branded NR (Niagen®) has NDI/GRAS notices.
Bottom line: Reliable NAD+ elevation; clinical endpoint wins remain modest/specific so far.
Nicotinamide mononucleotide (NMN)
Human data: At ≈250 mg/day for ~10 weeks, one RCT in a specific at-risk group improved skeletal muscle insulin sensitivity and increased NAD+ in PBMCs. Other populations show mixed effects.
Regulatory (U.S.): In Nov 2022 the FDA said NMN is excluded from the dietary supplement definition due to drug-investigation status; many retailers delisted it.
Bottom line: Interesting metabolic signals at study doses; U.S. retail availability is constrained.
Calcium alpha-ketoglutarate (Ca-AKG)
Evidence: In model organisms, α-ketoglutarate extends lifespan by dampening TOR and encouraging autophagy/maintenance. Human data are early; a retrospective analysis reported a notable epigenetic-age shift but needs blinded RCT confirmation.
Bottom line: Mechanistically compelling; human longevity outcomes remain preliminary.
Apigenin
Evidence: Dietary flavonoid (chamomile, parsley, celery) with preclinical effects on PI3K–Akt–mTOR/AMPK and autophagy.
Bottom line: Mechanistically interesting; human longevity data are limited. Prefer food sources while trials mature.
Dosing used in studies (context — not recommendations)
Always consult a clinician; these are study contexts, not advice.
| Molecule | Study doses (short phrases) |
|---|---|
| NR | 100–1,000 mg/day (6–12 wk); higher explored short-term |
| NMN | ~250 mg/day (6–12 wk) in key RCT; wider ranges tested |
| Ca-AKG | ~1–2 g/day in consumer use; RCT dosing TBD |
| Apigenin | No established longevity dose; products 50–200 mg/cap |
Typical monthly costs (illustrative ranges)
| Molecule | Monthly range |
|---|---|
| NR | ~$46–$116 (30–60 servings) |
| NMN | Varies by jurisdiction/retailer; often premium |
| Ca-AKG | ~$90–$110 (branded formulations) |
| Apigenin | ~$10–$30 (100–240 count; 100 mg) |
Regulatory status (U.S. quick-glance)
- NR (Niagen®): NDI acknowledged; GRAS notices on file.
- NMN: Excluded from supplement definition per FDA (Nov 2022) due to drug-investigation status; availability varies.
- Ca-AKG & Apigenin: Sold as dietary supplements; monitor evolving guidance. FDA does not “approve” supplements.
Mechanisms that matter (plain English)
- NAD+ → Sirtuins: NAD+ fuels sirtuin deacetylases tied to mitochondrial biogenesis, stress resistance, and metabolic flexibility.
- Autophagy & mTOR: α-KG can inhibit ATP synthase and suppress TOR, nudging cells toward repair/cleanup; apigenin interacts with PI3K–Akt–mTOR/AMPK axes in models.
Practical picks (educational—not medical advice)
- Most established NAD+ booster: NR (consistent NAD+ increases; clear U.S. regulatory footing).
- Metabolic focus and can navigate access issues: NMN (signals at 250 mg/day in a specific group; retail status constrained).
- Cellular-maintenance angle: Ca-AKG (promising mechanisms; wait for RCTs if you want clinical endpoints).
- Polyphenol preference: Apigenin (promising in models; prioritize whole-food sources for now).
Safety & smart stacking
- Avoid megadoses.
- Watch interactions (methylation balance, CYP enzymes).
- Lifestyle (training, protein, sleep, glycemic control) multiplies benefits.
FAQs
Does raising NAD+ guarantee slower aging?
No. NR/NMN raise NAD+ reliably, but human hard-outcome data are not conclusive.
Is NMN “banned” in the U.S.?
FDA said it’s excluded from the supplement definition due to drug-investigation status; policies can evolve by jurisdiction.
Most cost-effective NAD+ approach now?
Given regulatory clarity and pricing, many consumers start with NR. Compare per-mg costs and third-party testing.
References (reader-friendly)
- Human trials and reviews on NR/NMN raising NAD+; Yoshino et al. 2021 RCT on NMN and insulin sensitivity; FDA notices on NMN; α-KG mechanism/lifespan work; epigenetic-age retrospective; apigenin mechanism reviews.